Agios Pharma (AGIO) Tops Q2 EPS by 36c

Agios Pharma (NASDAQ: AGIO) reported Q2 EPS of ($1.19), $0.36 better than the analyst estimate of ($1.55). Revenue for the quarter came in at $40.41 million versus the consensus estimate of $11.28 million.

For earnings history and earnings-related data on Agios Pharma (AGIO) click here.

You May Also Be Interested In

• MillerKnoll, Inc. (MLKN) Tops Q1 EPS by 18c ; Offers Guidance
• AnaptysBio, Inc. (ANAB) Tops Q2 EPS by 524c
• UBS Reiterates Neutral Rating on Pilgrim's Pride (PPC) on 'Challenging' Near-Term Fundamentals